Attovia Therapeutics priced an upsized IPO at $289 million (sold 17 million shares at $17 each), putting the proceeds toward two planned Phase II trials in 2027 for ATTO-1310, an engineered biologic targeting IL-31. The company previously licensed its ATTOBODY platform from Alamar Biosciences and cited Phase Ib data showing rapid itch relief and lesion control in high-itch atopic dermatitis. Separately, Braveheart Bio priced a $382.5 million IPO to advance BHB-1893, an oral cardiac myosin inhibitor in Phase III for hypertrophic cardiomyopathy. With underwriting options and a staged global Phase III plan, Braveheart’s listing reflects continued appetite for genetics-driven cardiovascular programs. Taken together, the offerings show IPO investors backing late-preclinical-to-Phase II and Phase II-to-Phase III inflection points as funding for long timelines remains constrained.